Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 10Neoplasms 8Neoplasm Metastasis 8Endometrial Neoplasms 6Breast Neoplasms 6Brain Neoplasms 5Unspecified Adult Solid Tumor, Protocol Specific 4Prostatic Neoplasms 4Melanoma 4Lymphoma 4Kidney Neoplasms 4Glioblastoma 4Advanced Cancer 4Uterine Cervical Neoplasms 3Sarcoma 3Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Multiple Myeloma 3Glioma 3Central Nervous System Neoplasms 3Unspecified Childhood Solid Tumor, Protocol Specific 2Solid Tumors 2Small Cell Lung Carcinoma 2Resistant Solid Malignancies 2Pinealoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma, Mantle-Cell 2Lung Neoplasms 2

Interventions

temsirolimus 1rucaparib 1niraparib 1nintedanib 1atezolizumab 1Topotecan 1Paclitaxel 1Fulvestrant 1Cell Count 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Genital Neoplasms, Female × temsirolimus × Clear all
NCT00523432 2013-09-05

A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies

University of Chicago

Phase 1 Completed
15 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡